Difference between revisions of "Template:Article of the week"

From LIMSWiki
Jump to navigationJump to search
(Updated article of the week text)
(32 intermediate revisions by the same user not shown)
Line 1: Line 1:
<div style="float: left; margin: 0.5em 0.9em 0.4em 0em;">[[File:Fig1 Brusniak BMCBioinformatics2019 20.png|240px]]</div>
<div style="float: left; margin: 0.5em 0.9em 0.4em 0em;">[[File:Anx1 WHO 2020 2020.5.png|240px]]</div>
'''"[[Journal:Laboratory information management software for engineered mini-protein therapeutic workflow|Laboratory information management software for engineered mini-protein therapeutic workflow]]"'''
'''"[[Journal:Laboratory testing for coronavirus disease (COVID-19) in suspected human cases|Laboratory testing for coronavirus disease (COVID-19) in suspected human cases]]"'''


Protein-based therapeutics are one of the fastest growing classes of novel medical interventions in areas such as cancer, infectious disease, and inflammation. Protein engineering plays an important role in the optimization of desired therapeutic properties such as reducing immunogenicity, increasing stability for storage, increasing target specificity, etc. One category of protein therapeutics is nature-inspired bioengineered cystine-dense peptides (CDPs) for various biological targets. These engineered proteins are often further modified by synthetic chemistry. For example, candidate mini-proteins can be conjugated into active small molecule drugs. We refer to modified mini-proteins as "optides" (optimized peptides). To efficiently serve the multidisciplinary lab scientists with varied therapeutic portfolio research goals in a non-commercial setting, a cost-effective, extendable [[laboratory information management system]] (LIMS) is/was needed. ('''[[Journal:Laboratory information management software for engineered mini-protein therapeutic workflow|Full article...]]''')<br />
This document provides interim guidance to [[Laboratory|laboratories]] and stakeholders involved in [[COVID-19]] virus laboratory testing of patients. It is based in part on the interim guidance on laboratory testing for [[Middle East respiratory syndrome]] (MERS) coronavirus. [[Information]] on human [[infection]] with the COVID-19 virus is evolving and the [[World Health Organization]] (WHO) continues to monitor developments and revise recommendations as necessary. This document will be revised as new information becomes available. Feedback is welcome and can be sent to WHElab@who.int. The virus has now been named SARS-CoV-2 by the International Committee of Taxonomy of Viruses (ICTV)(2). This virus can cause the disease named coronavirus disease 2019 (COVID-19). WHO refers to the virus as COVID-19 virus in its current documentation. ('''[[Journal:A security review of local government using NIST CSF: A case study|Full article...]]''')<br />
<br />
<br />
''Recently featured'':
''Recently featured'':
: ▪ [[Journal:Defending our public biological databases as a global critical infrastructure|Defending our public biological databases as a global critical infrastructure]]
: ▪ [[Journal:One tool to find them all: A case of data integration and querying in a distributed LIMS platform|One tool to find them all: A case of data integration and querying in a distributed LIMS platform]]
: ▪ [[Journal:Determining the hospital information system (HIS) success rate: Development of a new instrument and case study|Determining the hospital information system (HIS) success rate: Development of a new instrument and case study]]
: ▪ [[Journal:What is the "source" of open-source hardware?|What is the "source" of open-source hardware?]]
: ▪ [[Journal:Smart information systems in cybersecurity: An ethical analysis|Smart information systems in cybersecurity: An ethical analysis]]
: ▪ [[Journal:From command-line bioinformatics to bioGUI|From command-line bioinformatics to bioGUI]]

Revision as of 15:46, 23 March 2020

Anx1 WHO 2020 2020.5.png

"Laboratory testing for coronavirus disease (COVID-19) in suspected human cases"

This document provides interim guidance to laboratories and stakeholders involved in COVID-19 virus laboratory testing of patients. It is based in part on the interim guidance on laboratory testing for Middle East respiratory syndrome (MERS) coronavirus. Information on human infection with the COVID-19 virus is evolving and the World Health Organization (WHO) continues to monitor developments and revise recommendations as necessary. This document will be revised as new information becomes available. Feedback is welcome and can be sent to WHElab@who.int. The virus has now been named SARS-CoV-2 by the International Committee of Taxonomy of Viruses (ICTV)(2). This virus can cause the disease named coronavirus disease 2019 (COVID-19). WHO refers to the virus as COVID-19 virus in its current documentation. (Full article...)

Recently featured:

▪ One tool to find them all: A case of data integration and querying in a distributed LIMS platform
▪ What is the "source" of open-source hardware?
▪ From command-line bioinformatics to bioGUI
Retrieved from "https://www.limswiki.org/index.php?title=Template:Article_of_the_week&oldid=38742"